---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-202506"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:54:29.806307+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Axsome Q1 revenue $191.2M (+57% YoY); Auvelity approved for Alzheimer's agitation

## Summary
- Total net product revenue $191.2M (+57% YoY); Auvelity $153.2M (+59%), Sunosi $33.9M (+34%), Symbravo $4.1M.
- Net loss $64.5M ($1.26/share) vs $59.4M ($1.22/share) YoY; cash $305.1M at March 31, 2026.
- FDA approved Auvelity for agitation in Alzheimer's disease (April 2026); full commercial launch expected June 2026.
- NDA submitted for AXS-12 (cataplexy in narcolepsy); pipeline expanded with AXS-20 (balipodect) for schizophrenia/Tourette.
- Cash guidance: current resources sufficient to fund operations into cash flow positivity.

## SEC filing metadata
- accession: 0001193125-26-202506
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/0001193125-26-202506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-202506
- JSON: https://secwatch.observer/filing/0001193125-26-202506.json
- Plain text: https://secwatch.observer/filing/0001193125-26-202506.txt

## Key facts
- Earnings Releases
  Axsome Therapeutics, Inc. reported first quarter of 2026 results: revenue $191.2 million, net income $(64.5) million, EPS $(1.26) per share.
  - Period: first quarter of 2026
  - Revenue: $191.2 million
  - Net income: $(64.5) million
  - EPS: $(1.26) per share
  - Result: reported results
  source text: Total net product revenue was $191.2 million for the first quarter of 2026, representing 57% year-over-year growth.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/0001193125-26-202506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.